ADAG
Price
$2.06
Change
-$0.34 (-14.17%)
Updated
Oct 16 closing price
Capitalization
214.86M
47 days until earnings call
Intraday BUY SELL Signals
CYTK
Price
$61.95
Change
-$1.97 (-3.08%)
Updated
Oct 16 closing price
Capitalization
9.2B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ADAG vs CYTK

ADAG vs CYTK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ADAG vs. CYTK commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAG is a Hold and CYTK is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ADAG with price predictions
Oct 15, 2026

Momentum Indicator for ADAG turns negative, indicating new downward trend

ADAG saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned negative. In 95 of the 101 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ADAG turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

The 50-day moving average for ADAG moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ADAG entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAG advanced for three days, in 178 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

ADAG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.402) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (17.606) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ADAG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for CYTK with price predictions
Oct 16, 2026

CYTK's RSI Oscillator ascends from oversold territory

The RSI Indicator for CYTK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 69 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on October 13, 2026. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in 45 of 57 cases over the following month. The odds of a continued upward trend are 79%.

Following a +3.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 216 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 83 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for CYTK entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (26.782). CYTK's P/E Ratio (702.500) is considerably higher than the industry average of (43.395). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (437.542).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
CYTK: Fundamental Ratings
CYTK
OUTLOOK RATING
1..100
71
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
PROFIT vs RISK RATING
1..100
74
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ADAGCYTK
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 18 days ago
84%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 1 day ago
67%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (ADAG: $2.06 vs. CYTK: $61.95)
Brand notoriety: ADAG and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAG: 123% vs. CYTK: 70%
Market capitalization -- ADAG: $214.86M vs. CYTK: $9.2B
ADAG [@Biotechnology] is valued at $214.86M. CYTK’s [@Biotechnology] market capitalization is $9.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAG’s FA Score shows that 1 FA rating(s) are green while CYTK’s FA Score has 1 green FA rating(s).

  • ADAG’s FA Score: 1 green, 4 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, both ADAG and CYTK are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAG’s TA Score shows that 4 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).

  • ADAG’s TA Score: 4 bullish, 5 bearish.
  • CYTK’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than ADAG.

Price Growth

ADAG (@Biotechnology) experienced а -25.36% price change this week, while CYTK (@Biotechnology) price change was -1.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

ADAG is expected to report earnings on Dec 02, 2026.

CYTK is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ADAG
Daily Signal:
Gain/Loss:
CYTK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MYCM23.61-0.01
-0.06%
State Street My2033 Corporate Bond ETF (MYCM)
FLJP40.46-0.17
-0.42%
Franklin FTSE Japan ETF (FLJP)
NXTG147.87-2.33
-1.55%
First Trust Indxx NextG ETF (NXTG)
ATCL24.12-0.38
-1.55%
Rex Autocallable Income ETF
LITX23.23-2.86
-10.96%
Tradr 2X Long LITE Daily ETF (LITX)

ADAG and

Correlation & Price change

A.I.dvisor tells us that ADAG and OCGN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ADAG and OCGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAG
1D Price
Change %
ADAG100%
-14.17%
OCGN - ADAG
29%
Poorly correlated
-4.10%
SLDB - ADAG
29%
Poorly correlated
-3.66%
CYTK - ADAG
28%
Poorly correlated
-3.08%
LENZ - ADAG
28%
Poorly correlated
-8.40%
GERN - ADAG
28%
Poorly correlated
-4.88%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with DARE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then DARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-3.08%
DARE - CYTK
42%
Loosely correlated
-2.08%
AXSM - CYTK
41%
Loosely correlated
-2.87%
BBIO - CYTK
41%
Loosely correlated
-1.10%
NAMS - CYTK
41%
Loosely correlated
-3.83%
VRDN - CYTK
40%
Loosely correlated
-2.71%
More